Phase 3 Glaucoma Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People aged 18 or older who are in good health
- People whose eyes (one or both) have been diagnosed with high-risk high eye pressure (pressure above 21 mmHg) without signs of glaucoma damage to the optic nerve
- People whose eyes (one or both) have been diagnosed with mild open-angle glaucoma, based on specific optic nerve and visual field test results
- People whose eyes (one or both) have been diagnosed with moderate open-angle glaucoma, based on specific optic nerve and visual field test results (the two eyes may have different diagnoses)
- People whose vision in each eye is at least 20/200 (or 6/60 in UK measurements), even with glasses or contact lenses
Who may not be able to join:
- People who have used eye drops to lower eye pressure for more than 6 months in total at any point in the past 5 years
- People who have previously had any laser treatment (other than a preventive procedure called prophylactic iridotomy) or surgery to lower eye pressure
- People who have advanced open-angle glaucoma in either eye (more severe than the moderate stage described above)
- People who have any type of glaucoma other than primary open-angle glaucoma in either eye, including pigmentary or pseudoexfoliation glaucoma
- People whose average eye pressure measured at the screening or baseline visit was above 35 mmHg in either eye
- People who have a narrow or closed drainage angle in either eye (confirm with trial site)
- People for whom the laser treatment used in this trial, or any other part of the study, would be medically unsuitable
- People who have a corneal condition in either eye that would prevent accurate eye pressure measurement using the standard clinical method
- People who have had any eye surgery in either eye within the past 6 months
- People who would be unable to attend all scheduled visits for the study
- People who are pregnant or planning to become pregnant within the next 4 years
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Tony Realini, MD, MPH, West Virginia University
Phone: 3045986926
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
12-month survival; 48-month survival
Can't join this trial?
Data last synced from ClinicalTrials.gov: 27 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.